Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial.

What was studied

This early-stage trial tested a drug called trastuzumab deruxtecan, or T-DXd. It included people with lung cancer that had spread. All had been treated for their cancer before. Their cancer made too much of a protein called HER2. Some got T-DXd with durvalumab and cisplatin, a chemo drug. Others got T-DXd with durvalumab and carboplatin, or T-DXd on its own.

What they found

The cisplatin group had 11 people, and the carboplatin group had 24. The group on T-DXd alone had 36 people. Both mixed groups had harms that limited the dose they could give. These harms were fever with low white cells and low platelet counts. Some of these harms led to death. Serious drug-linked harms were more common in the mixed groups than with T-DXd alone. Tumors shrank in some people in the carboplatin group. They also shrank in some people on T-DXd alone.

What it means for patients

The authors say this trial backs up that T-DXd alone acts against this cancer. They say the results do not back adding durvalumab and platinum chemo to T-DXd. This applies to people whose HER2 lung cancer had prior treatment.

Why it is not certain yet

This was an early-stage trial, mainly meant to check safety. The abstract does not describe a group on standard care for comparison. People and doctors knew which drugs were given. Study doctors judged whether the tumors shrank. The abstract does not say how long any tumor shrinking lasted.

Source

Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial.

We restate facts from the source record in our own words. The original wording belongs to its publisher.